ID: ALA85676

Max Phase: Preclinical

Molecular Formula: C26H27N5O6

Molecular Weight: 505.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)c1ccc(NC(=O)NC(=O)N2CCN(C(=O)CN3C(=O)C(=O)c4cc(C)cc(C)c43)CC2)cc1

Standard InChI:  InChI=1S/C26H27N5O6/c1-15-12-16(2)22-20(13-15)23(34)24(35)31(22)14-21(33)29-8-10-30(11-9-29)26(37)28-25(36)27-19-6-4-18(5-7-19)17(3)32/h4-7,12-13H,8-11,14H2,1-3H3,(H2,27,28,36,37)

Standard InChI Key:  WZQQPWOIDVPSDS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 505.53

Molecular Weight (Monoisotopic): 505.1961

AlogP: 2.12

#Rotatable Bonds: 4

Polar Surface Area: 136.20

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.02

CX Basic pKa:

CX LogP: 1.16

CX LogD: 1.16

Aromatic Rings: 2

Heavy Atoms: 37

QED Weighted: 0.48

Np Likeness Score: -1.32

References

1. Shuttleworth SJ, Nasturica D, Gervais C, Siddiqui MA, Rando RF, Lee N..  (2000)  Parallel synthesis of isatin-based serine protease inhibitors.,  10  (22): [PMID:11086715] [10.1016/s0960-894x(00)00523-0]

Source

Source(1):

• Scientific Literature